Furthermore, we previously observed the upregulation of IL-18 in NASH patients compared to healthy controls [18], which may be associated with the increased expression of IL-18R1 at 96 w in our study. This evidence concerns the gene IL18R1 and metabolic dysfunction-associated steatohepatitis.